AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04469309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group I Brandt-Daroff Exercises
Description: In group I Brandoff Exercises will be performed using standard method, in which the patient is in the sitting position on examination table, the patient moves into the lying position on the affected side on the shoulder, with the head angled upward with about 45. The patient stays in this for 30 s and then goes back to the sitting position, looks forward and remains in this position for 30 s as well. The patient repeats the same procedure for the other side, too.~The patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks. Pre, mid and post assessment.
Study NCT04469309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group II Half-Somersault Maneuver
Description: In group II Half-Somersault Maneuver will be done, the patient performs this maneuver 2 times, twice a day. For total 9 days for 3 weeks.
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Urine sampling
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Carry a GPS and BET
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Carry pollution sensor
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Sampling at the maternity
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaires
Study NCT02852499 — intervention group
Intervention type: OTHER
Intervention: Sampling in partum period
Description: Meconium and a strand of hair.
Study NCT05114811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-provided perineal massage
Description: External massage should be applied with pump of the perineum central core. Internal massage should be applied intracavitary with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.
Study NCT05114811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapist perineal massage: manual and instrumental (with EPI-NO)
Description: The treatment sequence included external massage with two manouvres: vulvar drainage and pump of the perineum central core. Intracavitary techniques were then applied through three maneuvers: massage with longitudinal glides, myofascial trigger points of pelvic diaphragm and streching.~After this, instrumental massage was applied with the EPI-NO® device.
Study NCT03370588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
Study NCT03370588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Group B: Saline infusion during same time period.
Study NCT00595764 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual-guided Physician Management (PM)
Description: Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
Study NCT00595764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)
Description: CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
Study NCT01588522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: compound 31543 Calcitriol
Description: topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
Study NCT03159494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Training
Description: 8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed
Study NCT00589628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 5mg/kg/dose IV at 4 week intervals
Study NCT00589628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: 10mg/kg/dose IV at 4 week intervals
Study NCT00936065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
Study NCT00936065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept + Acitretin
Description: Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
Study NCT02024724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 4 mL of 0.25% bupivacaine
Study NCT02024724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: 40 mg of Triamcinolone
Study NCT00936065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: Acitretin at a dose of 10mg BID for 24 weeks
Study NCT00939211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Solution for inhalation through nebulization, single dose
Study NCT02970487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular implant of the Precisight
Description: Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
Study NCT03062709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe Easy Coalition written materials
Description: written materials about secondhand and thirdhand environmental smoke exposure in children
Study NCT03062709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maine Tobacco Helpline
Description: referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
Study NCT03062709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cotinine testing
Description: the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
Study NCT02885402 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI Sodium ( 23Na )
Study NCT02885402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI Sodium ( 23Na )
Study NCT02024724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg of Dexamethasone
Study NCT01430520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
Study NCT01430520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
Study NCT02312934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Description: Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
Study NCT02312934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Transdermal Patch
Description: Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.
Study NCT03503617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehabTouch
Description: Exercise using the motion sensing devices and a computer
Study NCT03503617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional tabletop exercise program
Description: Exercise following printed sheets of exercises
Study NCT02074657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated and expanded natural killer cells (NKAEs)
Description: Activated and expanded natural killer cells (NKAEs) from haploidentical donor
Study NCT03205605 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: patch
Study NCT03205605 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxybutynin
Description: gel
Study NCT02815007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide with EGFR-TKI
Description: Chidamide and EGFR-TKI, dosage described in arm description.
Study NCT01815996 — intervention group
Intervention type: OTHER
Intervention: One time blood draw to look at patient's DNA
Description: One time blood draw to look at patient's DNA
Study NCT02439021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA
Study NCT02439021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA
Study NCT00825786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: ropivacaine (15 ml).
Study NCT00825786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: One syringe will contain mepivacaine (15 ml)
Study NCT01231646 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention. This is a cross-sectional study.
Study NCT01101113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinacalcet
Description: cinacalcet 25mg qd or 50 mg qd
Study NCT01101113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: vit D + P binder
Study NCT03716362 — intervention group
Intervention type: DEVICE
Intervention: Otoacoustic emissions device
Description: as a screening tool for Auditory brainstem response
Study NCT01005147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Description: 1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
Study NCT01005147 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will receive placebo treatment as per the tranexamic acid schedule
Study NCT01183169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisporivir
Description: ALV 200 mg soft gel capsules administered orally
Study NCT00258960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Liposomal Doxorubicin
Study NCT00258960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Study NCT00258960 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Study NCT02367976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhprouk
Description: rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
Study NCT02992509 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EMED detruset(TM) intravesical electrical stimulation
Description: There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered.
Study NCT00916019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 60 min of low-intensity exercise, 5 days/week, 12 weeks
Study NCT00651274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
Study NCT00651274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
Study NCT02189837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT00748319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Detection of KIR receptor by RT PCR
Description: Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
Study NCT00005818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00005818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Description: Given IV
Study NCT01183169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
Study NCT01183169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: RBV 200 mg tablets (weight-based dose: \< 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
Study NCT01183169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ALV placebo soft gel capsules administered orally
Study NCT01514396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiseal
Description: surgical glue
Study NCT01166828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TELLEPUPPS
Description: The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
Study NCT01166828 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TELLEPUPPS
Description: The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
Study NCT00005818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04077515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus(0.8mg/m2)
Description: The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Study NCT04077515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus(0.7mg/m2)
Description: The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
Study NCT03042884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete.
Study NCT00939211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Dry powder for inhalation, single dose
Study NCT00939211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00972309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell receptor alternate reading frame protein (TARP) peptide vaccine
Description: Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF). TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
Study NCT00972309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
Description: Will receive peptide pulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
Study NCT01687985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 laxative - low dose
Description: BLI801 laxative - oral solution
Study NCT01687985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 laxative - high dose
Description: BLI801 laxative - oral solution
Study NCT00216112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Imatinib mesylate 600 mg po qd
Study NCT00216112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
Study NCT03459092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin injection in the horizontal extraocular muscles.
Study NCT03459092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strabismus surgery
Description: Strabismus surgery on the horizontal extraocular muscles
Study NCT03459092 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strabismus surgery
Description: Strabismus surgery on the horizontal extraocular muscles
Study NCT01028599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physical exercise
Description: Intensive physical exercise 1 hour three times per week
Study NCT01851031 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: the minor approach
Description: Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
Study NCT01851031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the minor approach
Description: Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
Study NCT03016520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1392
Study NCT03016520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC20164
Study NCT04495166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motherly 1.0
Description: A mobile app designed to promote life habits that have been shown to improve physical and mental health in pregnant women. The app consists of a package of specific and customized interventions defined by eight different modules: 1) Mental Health; 2) Sleep; 3) Nutrition; 4) Physical activity; 5) Social support; 6) Prenatal support; 7) Postnatal support, and 8) Library of pre and postnatal content. The app relies on extensive psychoeducational content delivered as tutorials, brief messages, and available as a library that can be read at the users' discretion; behavior monitoring using schedules, checklists, and notifications to help participants keep track of their health care visits, and schedule behavior activation activities; and gaming elements such as changes in background appearance to reflect participant's mood assessment and ratings of activities, and graphical and easy-to-use questionnaires for obtaining information (mood, nutrition habits).
Study NCT04495166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Psychotherapy
Description: Brief Cognitive-Behavioral Therapy (CBT) with a focus on behavioral activation (BA). Participants will be guided by psychotherapists to plan, schedule, and engage in positively reinforcing activities, and will be aided to develop problem-solving strategies for circumventing barriers to completing scheduled activities. Implementation of these techniques will be conducted with the aid of the Motherly 1.0 for participants in the experimental arm; for participants in the control arm, BA will be implemented without the aid of Motherly 1.0. Throughout the four sessions, psychotherapists will monitor participants' adherence, answering questions about the strategies and providing support for solving problems or CBT techniques, such as cognitive restructuring, relaxation techniques, sleep hygiene, stress and anxiety management, among other evidence-based techniques might be used if appropriate to the case.